homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

August 4, 2020

Alpine Immune Sciences

In Seattle, Alpine Immune Sciences entered into a $60 million private stock placement led by Omega Funds with participation from Avidity Partners, EcoR1 Capital, Invus Public Equities and Samsara BioCapital. The money and existing cash are expected to fund development of the company's preclinical and clinical pipeline through 2024. Alpine is using immunotherapy to treat cancer, autoimmune/inflammatory and other diseases.




Email or user name:
Password:
 
Forgot password? Click here.